INTIMATION FOR BODHIKA SEMINAR 25/10/2023
DEPARTMENT OF PRASUTI TANTRA & STREEROGA
RASASHASTRA & BHAISHAJYA KALPANA
NAME OF FIRST PRESENTEE:DR. SRUTHI L R
DISSERTATION TITLE: COMBINED EFFECT OF RAJAPRAVARTINI VATI AND CHIRUVILWADI KASHAYA IN OLIGOMENORRHOEA ASSOCIATED WITH POLYCYSTIC OVARIAN SYNDROME
TIME: 2:00-4:00 PM
VENUE: COLLEGE AUDITORIUM
ABSTRACT
Polycystic Ovarian Syndrome is one of the most common metabolic &reproductive disorder among women of reproductive age. Changes in the lifestyle, diet, stress of modern society leads to increase in prevalence of PCOS upto 20-30%. PCOS effects the richness of feminity as infertility stands out as one of its major complications. Oligomenorrhoea is one among the most common presenting complaints in participants diagnosed with PCOS. Although no direct correlation of PCOS is found in ayurvedic classical texts. Etiopathogenesis of nastharthava, arhavakshaya, and vandhya yoni vyapath mentioned in susrutha samhitha can be considered here. Pushpagni jataharini mentioned in Kasyapa samhitha bears some similarity with this disease. Here the combined effect of Rajapravartini vati & chiruvilwadi kashaya in Oligomenorrhoea associated with PCOS were evaluated. The study drug Rajapravartini vati is mentioned under streerogadhikara in bhaishajyaratnavali and Chiruvilwadi kashaya is mentioned under arsas prakaranam in sahasrayogam. The study design is pre and post interventional study with a sample size of 30. Females in age group of 18-40 years diagnosed as having Oligomenorrhoea associated with PCOS as per Rotterdam criteria 2003, satisfying inclusion and exclusion criteria attending the OPD of Dept of Prasutitantra and streeroga, Govt Ayurveda College, Thiruvananthapuram were selected for the study. Their symptoms were assessed before starting the treatment using a case proforma, USG and necessary lab investigations. In this study 125 mg of Rajapravartini vati followed by intake of 48 ml of Chiruvilwadi kashaya twice daily before food were adviced to the participants for 90 days. Administration of drug starts on the 1st day of visit and continued till the onset of next menstrual cycle excluding the 3 days of menstruation for three consecutive cycles. Follow up without medicines was done for next 3 consecutive cycles. Data obtained was analysed statistically. The study drug was found to be effective in normalizing menstrual interval, reducing the ovarian volume and reducing the BMI, without causing changes in duration of menstruation, amount of bleeding and haemoglobin level with in the study period.